amifostine trihydrate

Phase 3Small molecule

amifostine trihydrate is one of 526 small molecule programs targeting Primary Systemic Amyloidosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

525

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary Systemic AmyloidosisActive, not recruiting

Primitive Neuroectodermal TumorActive, not recruiting

Peripheral NeuropathyActive, not recruiting

Germ Cell TumorActive, not recruiting

LeukemiaActive, not recruiting

Liver CancerActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

XerostomiaActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Primary Systemic AmyloidosisPhase 1

Active, not recruiting

Primitive Neuroectodermal TumorPhase 2

Active, not recruiting

Peripheral NeuropathyPhase 3

Active, not recruiting

Germ Cell TumorPhase 2

Active, not recruiting

LeukemiaPhase 2

Active, not recruiting

Liver CancerPhase 3

Active, not recruiting

Metastatic Colorectal CancerPhase 1/Phase 2

Active, not recruiting

XerostomiaPhase 2

Active, not recruiting

Myelodysplastic SyndromePhase 1/Phase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Showing 10 of 20 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

amifostine trihydrate

GGynecologic Oncology Group

Phase 3

2 2

MS Contin

Merck & Co.

Preclinical

2 3

Lexiscan

Astellas

Preclinical

1 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

Adenocard

Astellas

Preclinical

1 6

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 7

Spravato

WWim Janssens

Preclinical

2 8

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 9

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 10

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myelodysplastic Syndrome6 trials

Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome

Unknown status·AALZA·Phase 2·NCT00003827·25 enrolled

Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00003681·50 enrolled

Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00005598

Show 3 more trials

Amifostine in Treating Patients With Myelodysplastic Syndrome

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00003048·12 enrolled

Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome

Completed·UUniversity of Arizona·Phase 1/2·NCT00003415·26 enrolled

Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome

Unknown status·—·Phase 2·NCT00003123·36 enrolled

Non-Small Cell Lung Cancer4 trials

Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00003313·243 enrolled

Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer

Completed·UUniversity of California, San Francisco·Phase 2·NCT00003072·80 enrolled

Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer

Unknown status·UUniversity of Wisconsin, Madison·Phase 1/2·NCT00004264

Show 1 more trial

Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT00003089

Head and Neck Cancer3 trials

Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer

Completed·UUniversity of Miami·Phase 1/2·NCT00003582·36 enrolled

Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer

Unknown status·UUniversity of Illinois at Chicago·Phase 1/2·NCT00003251·46 enrolled

Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Completed·MMassachusetts General Hospital·Phase 1/2·NCT00003193·37 enrolled

Small Cell Lung Cancer3 trials

Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer

Unknown status·UUniversity of Florida·Phase 2·NCT00003583·20 enrolled

Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT00004176·34 enrolled

Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT00006012·73 enrolled

Chemotherapy2 trials

Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML

Withdrawn·RRush University Medical Center·Phase 2·NCT00003407

Amifostine in Treating Patients With Cancer Who Have Neurological Changes Caused by Chemotherapy

Completed·—·Phase 4·NCT00003252

28 more indications

Primitive Neuroectodermal Tumor2 trials

Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00002643·130 enrolled

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT00003211·94 enrolled

Recurrent or Refractory Solid Tumors2 trials

Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors

Completed·SState University of New York - Upstate Medical University·Phase 1·NCT00003555·20 enrolled

Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors

Completed·NNYU Langone Health·Phase 1·NCT00003144·44 enrolled

Breast Cancer2 trials

High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer

Completed·UUniversity of Arizona·Phase 2·NCT00003068·30 enrolled

Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

Completed·—·Phase 1·NCT00003927·15 enrolled

Endometrial Cancer2 trials

S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT00003127·57 enrolled

Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer

Terminated·GGynecologic Oncology Group·Phase 2·NCT00003624

Prostate Cancer2 trials

Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer

Completed·UUniversity of Arizona·Phase 2·NCT00003307·25 enrolled

Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00040365·30 enrolled

Ovarian Cancer1 trial

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Completed·UUniversity of Chicago·Phase 1/2·NCT00003136·11 enrolled

Patients With Solid Tumors1 trial

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00003926·13 enrolled

Metastatic Colorectal Cancer1 trial

Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer

Completed·JJonsson Comprehensive Cancer Center·Phase 1/2·NCT00003225·23 enrolled

Leukemia1 trial

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia

Withdrawn·RRush University Medical Center·Phase 2·NCT00003405

Recurrent or Metastatic1 trial

Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer

Completed·RRoswell Park Cancer Institute·Phase 1·NCT00003294·24 enrolled

Acute Myeloid Leukemia1 trial

Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1·NCT00003268

Cervical Cancer1 trial

Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 1/2·NCT00012012·45 enrolled

Primary Systemic Amyloidosis1 trial

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Terminated·EEastern Cooperative Oncology Group·Phase 1·NCT00052884·8 enrolled

Locally Advanced Cancer1 trial

Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00025298·5 enrolled

Germ Cell Tumor1 trial

Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors

Completed·CChildren's Oncology Group·Phase 2·NCT00003811·27 enrolled

Advanced Cancer1 trial

Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer

Unknown status·TThe Cleveland Clinic·Phase 1·NCT00004036·30 enrolled

Recurrent Head and Neck Cancer1 trial

Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer

Terminated·—·Phase 2·NCT00003777·35 enrolled

Myelodysplastic Syndromes1 trial

Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes

Completed·CChildren's Oncology Group·Phase 2·NCT00098683·10 enrolled

Bladder Cancer1 trial

Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer

Completed·UUniversity of Chicago·Phase 2·NCT00006105·37 enrolled

Multiple Myeloma1 trial

Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT00217438·130 enrolled

Xerostomia1 trial

Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia

Terminated·VVanderbilt-Ingram Cancer Center·Phase 2·NCT00503776·41 enrolled

Ovarian Epithelial Cancer1 trial

Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy

Completed·NNorthwestern University·Phase 3·NCT00004166

Solid Tumors1 trial

Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00004919·30 enrolled

Hematologic Cancer1 trial

Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors

Completed·SScripps Health·Phase 2·NCT00003269·20 enrolled

Advanced Head and Neck Cancer1 trial

Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer

Completed·UUniversity of Tennessee·Phase 2·NCT00003580

Peripheral Neuropathy1 trial

Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer

Completed·GGynecologic Oncology Group·Phase 3·NCT00058071·100 enrolled

Liver Cancer1 trial

Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer

Completed·CChildren's Oncology Group·Phase 3·NCT00003994·277 enrolled

SCS1 trial

Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect

Completed·UUniversity of Kentucky·Phase 1/2·NCT00003425·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 51 trial records for amifostine trihydrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — amifostine trihydrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for amifostine trihydrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gynecologic Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGynecologic Oncology Group

amifostine trihydrate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myelodysplastic Syndrome6 trials

Non-Small Cell Lung Cancer4 trials

Head and Neck Cancer3 trials

Small Cell Lung Cancer3 trials

Chemotherapy2 trials

Primitive Neuroectodermal Tumor2 trials

Recurrent or Refractory Solid Tumors2 trials

Breast Cancer2 trials

Endometrial Cancer2 trials

Prostate Cancer2 trials

Ovarian Cancer1 trial

Patients With Solid Tumors1 trial

Metastatic Colorectal Cancer1 trial

Leukemia1 trial

Recurrent or Metastatic1 trial

Acute Myeloid Leukemia1 trial

Cervical Cancer1 trial

Primary Systemic Amyloidosis1 trial

Locally Advanced Cancer1 trial

Germ Cell Tumor1 trial

Advanced Cancer1 trial

Recurrent Head and Neck Cancer1 trial

Myelodysplastic Syndromes1 trial

Bladder Cancer1 trial

Multiple Myeloma1 trial

Xerostomia1 trial

Ovarian Epithelial Cancer1 trial

Solid Tumors1 trial

Hematologic Cancer1 trial

Advanced Head and Neck Cancer1 trial

Peripheral Neuropathy1 trial

Liver Cancer1 trial

SCS1 trial

References

Drug Info

Quick Facts

Related News